share_log

Exicure | NT 10-K: Others

Exicure | NT 10-K: Others

Exicure | NT 10-K:其他
美股SEC公告 ·  04/01 16:26
Moomoo AI 已提取核心訊息
Exicure, Inc. has announced that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, within the prescribed time period. The delay is due to the company finalizing certain accounting treatments and completing necessary reviews. This includes the restatement of its financial statements for the first and second quarters of 2023, as well as completing and filing the related Form 10-Q amendments and its third quarter financial statements. Consequently, Exicure does not expect to meet the original filing deadline for the Annual Report. The company has also not yet filed its Form 10-Q for the third quarter of 2023. Exicure anticipates a significant change in its results of operations compared to the previous...Show More
Exicure, Inc. has announced that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, within the prescribed time period. The delay is due to the company finalizing certain accounting treatments and completing necessary reviews. This includes the restatement of its financial statements for the first and second quarters of 2023, as well as completing and filing the related Form 10-Q amendments and its third quarter financial statements. Consequently, Exicure does not expect to meet the original filing deadline for the Annual Report. The company has also not yet filed its Form 10-Q for the third quarter of 2023. Exicure anticipates a significant change in its results of operations compared to the previous fiscal year, which will be reflected in the earnings statements. This change is attributed to a major reduction in workforce, suspension of preclinical activities, and cessation of all research and development activities announced in September 2022, as the company explores strategic alternatives. While research and development expenses have substantially decreased, general and administrative expenses are expected to be higher than the previous year. The notification was signed by Paul Kang, Chief Executive Officer, on April 1, 2024.
Exicure, Inc.宣佈,它將無法在規定的期限內提交截至2023年12月31日財年的10-K表年度報告。延遲是由於該公司完成了某些會計處理並完成了必要的審查。這包括重報其2023年第一和第二季度的財務報表,以及完成和提交相關的10-Q表修正案及其第三季度財務報表。因此,Exicure預計不會在年度報告的原始提交截止日期之前提交。該公司也尚未提交2023年第三季度的10-Q表格。Exicure預計,與上一財年相比,其經營業績將發生重大變化,這將反映在收益報表中。這一變化歸因於公司在探索戰略替代方案時於2022年9月宣佈大幅裁員、暫停臨床前活動以及停止所有研發活動。儘管研發費用已大幅減少,但一般和管理費用預計將高於上一年。該通知由首席執行官保羅·康於2024年4月1日簽署。
Exicure, Inc.宣佈,它將無法在規定的期限內提交截至2023年12月31日財年的10-K表年度報告。延遲是由於該公司完成了某些會計處理並完成了必要的審查。這包括重報其2023年第一和第二季度的財務報表,以及完成和提交相關的10-Q表修正案及其第三季度財務報表。因此,Exicure預計不會在年度報告的原始提交截止日期之前提交。該公司也尚未提交2023年第三季度的10-Q表格。Exicure預計,與上一財年相比,其經營業績將發生重大變化,這將反映在收益報表中。這一變化歸因於公司在探索戰略替代方案時於2022年9月宣佈大幅裁員、暫停臨床前活動以及停止所有研發活動。儘管研發費用已大幅減少,但一般和管理費用預計將高於上一年。該通知由首席執行官保羅·康於2024年4月1日簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息